+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 16Years - 50Years
All Genders
ID07282210

Evaluating Senicapoc SIL-8301 Versus Placebo for Hemolytic Sickle Cell Disease Control with Hydroxyurea in Adults and Adolescents A Randomized, Double-Blind Study Including an Open-Label Extension

Led by Biossil Inc. · Updated on 2026-11-02

65

Participants Needed

4

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of SIL-8301 senicapoc for treating sickle cell disease SCD in adults and children who have a predominantly hemolytic form of the disease. The study focuses on patients with fewer than two acute sickle-related painful crises per year over the past two years, a baseline hemoglobin level of 9.5 gdL or less, and who are already receiving hydroxyurea as standard care. This Phase 2 trial aims to compare senicapoc with a placebo to understand its impact on controlling hemolysis in this patient group. Participants will be randomly assigned to receive either senicapoc or a matching placebo. Senicapoc is given as 20 mg twice daily for the first 4 days, followed by 10 mg once daily for up to 24 weeks, while the placebo is administered on the same schedule. All participants will continue their prescribed hydroxyurea treatment throughout the study. Those who complete the initial 24-week period may opt to join an open-label extension to receive senicapoc for up to two years. During the study, participants will be monitored regularly to assess changes in hemoglobin levels, markers of hemolysis like lactate dehydrogenase and bilirubin, reticulocyte count, and the frequency of sickle cell-related complications. Patient-reported outcomes and overall safety, including adverse event monitoring, will also be evaluated. The primary outcome is the hemoglobin response after 24 weeks, with follow-up continuing through the extension period, ensuring comprehensive assessment of both efficacy and safety over time.

CONDITIONS

Brief Title

Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype

Research Team

H

Head of Clinical Operations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here